Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US

  • Just a day after European approvalAlbireo Pharma Inc ALBO has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC).
  • PFIC afflicts children with severe, progressive liver disease.
  • The FDA approved Bylvay based on phase 3 trials showing that the drug can help ease pruritus and reduce serum bile acids. It isn't yet known whether it can reduce the need for liver transplants.
  • The approval marks a high point for the company, spun out of AstraZeneca PLC AZN way back in 2008.
  • Since then, it went public through a reverse merger and was later forced to shed its nonalcoholic steatohepatitis (NASH) candidate. It failed to achieve proof-of-concept for key NASH measures.
  • FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV), which the company plans to monetize.
  • It had cash and cash equivalents of $186.3 million as of June 30 and anticipates the 2021 operating cash burn of $130 million to $135 million.
  • Excluding any proceeds from the planned sale of the PRV, the company believes that its cash balance will fund its expenses into 2023.
  • Albireo is kicking off an "immediate" launch.
  • Price Action: ALBO shares are up 3.41% at $35.50 during the premarket session on the last check Wednesday.

Posted In: BriefsLiver DiseasePediatricsBiotechNewsHealth CareSmall CapFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.